Cytokinetics, Inc. (CYTK)

[Solantey]

After listening to the conference call I would conclude that the bottom is in here. The potential milestone payments and royalties are in excess of $1 billion dollars with the possibility of other partnership to be established.

Anyone who sold on April 25 will be able to buy back in next Tuesday and under the "wash rule" be able to claim the losses that might have resulted from those sales.

Too many potential catalysts to keep the share price so low for much longer. I expect the shorts will start covering as the share price rises and move to stocks with more volatility and more potential to the downside.

Risk/reward favors buying here.

All IMHO.